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Volume 48, Number 2 Rockman 285In terms of treatment of type II endoleak, that was up to the
investigator. Most of us tended to treat endoleaks only if the
aneurysms were increasing in size. Early in the experience, I
believe that majority of type II endoleaks treated were done by
in whom more relaxed surveillance regimens may be appropriate.
However, there was a 10.5% risk of ARM at 5 years in patients whocoil embolization. Translumbar glue embolization really wasn’t
being used with great frequency during this time, but perhaps
in the latter part of the trial, was used with some increased
frequency.INVITED COMMENTARYCaron Rockman, MD, New York, NY
The issue of the absolute necessity of life-long surveillance in
patients who have undergone endovascular abdominal aortic an-
eurysm repair (EVAR) is certainly an important and timely topic
from a number of perspectives. Clearly, there are appropriate
medical concerns regarding the repetitive use of iodinated contrast
materials and their possible cumulative deleterious effects on renal
function as well as apprehension regarding potential carcinogenic
consequences of recurring radiation exposure. In addition, the
issue of the societal cost of these studies cannot be completely
overlooked from a global health care standpoint.
To address these concerns, a variety of alternative forms of
surveillance in EVAR patients have been proposed, including
noncontrast computed tomography (CT) studies, traditional and
contrast-enhanced duplex ultrasound, gadolinium-enhanced mag-
netic resonance imaging, implantable wireless sac pressure sensors,
and intravascular ultrasound. However, currently the precise role
and accuracy of these alternatives remains ill defined.
The current study presents notable information. Patients with
an absence of early endoleak on a 30-day CT scan had a significant
reduction in aneurysm-related morbidity (ARM) at 1 to 5 years. It
should be noted, however, that although the definition of ARM
included obvious events such as aneurysm-related death, rupture,
endograft migration, and open conversion, it also included “sec-
ondary interventions,” which intuitively would be expected to be
more prevalent in patients with known endoleaks. Patients with a
cumulative absence of endoleak at 6 months (79.4% of patients)
and at 1 year (77.6% of patients), however, had an identical 5-year
freedom from any type of ARM. The authors state, therefore, that
routine surveillance for continued absence of endoleak at 6months
and 1 year did not greatly alter the predicted 5-year freedom from
ARM.
They conclude that the absence of an early endoleak therefore
identifies a cohort of patients at substantially reduced risk for ARMhad never experienced an endoleak. In addition, it is correctly
pointed out that not all ARM (for example, graft limb thrombosis)
will necessarily be predicted by an abnormality seen on a routinely
performed imaging study; nor can all ARM be prevented by even
very aggressive surveillance and monitoring programs.
Finally, in the Zenith trials there was a population of patients
in whom a delayed endoleak occurred: A 12% to 15% risk of late
endoleak, most often of type II, was noted even when no leak was
identified on the initial 30-day CT scan. The clinical significance of
these delayed leaks remains unclear. At our institution we have
anecdotally seen a number of patients in whom 3 or 4 years of
initially negative CT follow-up was subsequently followed by the
novel appearance of an endoleak on the next annual CT scan.
Several of these late leaks eventually required secondary interven-
tion and treatment.
The recommendations of the current study, although attrac-
tive, should be interpreted with caution. As the authors correctly
point out, these excellent results were obtained only using one type
of commercially available aortic stent graft system. In addition, and
perhaps even more importantly, these results were obtained in
patients who underwent intervention as part of a strictly controlled
clinical trial. As such, these patients represent a cohort of cases with
ideal anatomic parameters, and the long-term results are likely not
applicable to post-trial EVAR cases, in which preoperative ana-
tomic selection criteria is likely to have been relaxed by the indi-
vidual practitioner.
If the algorithm adopted in the article had been strictly fol-
lowed in this cohort of patients, this would have resulted in 23.4%
of patients having no routinely prescribed follow-up except for a
yearly ultrasound study after their negative result on the 1-year CT
scan. Even this excellent and compelling data and analysis do not
support such a radical change in follow-up protocols at the present
time. Although there undoubtedly exists a cohort of patients who
may not require lifelong intensive surveillance imaging after
EVAR, they remain imprecisely characterized at the present time.
